MediciNova, Inc.
　　Message from CEO
　　Our Mission
　　Company Profile
　　Management Team
　　History
　　Ongoing Clinical Studies
　　　　About MN-166 (Ibudilast)
　　　　ALS
　　　　Oncology / Glioblastoma
　　　　DCM
　　　　CIPN
　　　　ARDS / Lung Injury
　　　　About MN-001（Tipelukast)
　　　　NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
　　Press Release
　　Event
　　Media Archive
　　Annual Report
　　SEC filing
　　Stock Quote -TSE
　　Stock Quote -Nasdaq
　　Historical Price Lookup
　　Investment Calculator
　　Analyst Coverage
　　Corporate Governance
　　Information Request
　　Corporate Presentation & Resarch Reports
　　　　Progressive Multiple Sclerosis (Progressive MS)
　　　　Amyotrophic Lateral Sclerosis (ALS)
　　　　Oncology / Glioblastoma
　　　　Substance Dependence and Addiction
　　　　MN-166 (ibudilast) News Articles
　　　　MN-166 (ibudilast) Publications
　　MN-001 Presentation
　　Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001（Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Investor Relations
    • Press Release
    • Event
    • Media Archive
    • Annual Report
    • SEC filing
    • Stock Quote -TSE
    • Stock Quote -Nasdaq
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
    • Corporate Governance
    • Information Request
  • Presentation
    • Corporate Presentation and Equity Research Analyst Reports
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Contact Us

MediciNova to Participate at the 38th Annual ROTH Conference

2026.03.162026.05.13
Page Top
Keenan Flogerzi
MediciNova, Inc.

関連記事

MN-001

MN-001に対する中国における特許承認のお知らせ

MN-166

MN-166の進行型多発性硬化症を適応とするフェーズ2b臨床治験に関してトップラインデータ発表アブストラクトの第7回ECTRIMS-ACTRIMS合同学術集会レイトブレイキングセッションでの発表採択のお知らせ

MN-166

第39回アルコール中毒症研究会議年次総会における アルコール依存症を適応とするMN-166の臨床治験の追加解析による知見発表のお知らせ

MN-029

MN-029 (デニブリン)二塩酸塩に対する中国における特許承認のお知らせ

MN-166

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MN-001

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001（Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Investor Relations
      • Press Release
      • Event
      • Media Archive
      • Annual Report
      • SEC filing
      • Stock Quote -TSE
      • Stock Quote -Nasdaq
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
      • Corporate Governance
      • Information Request
    • Presentation
      • Corporate Presentation and Equity Research Analyst Reports
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Contact Us
  • MediciNova, Inc.